CHICAGO (GenomeWeb) – A PI3 kinase inhibitor called taselisib showed efficacy for the first time against patients with a solid tumor characterized by PIK3CA mutations.

And while the results of the trial weren't convincing enough for the drug's sponsor to continue to pursue US Food and Drug Administration approval, experts at the American Society of Clinical Oncology’s annual meeting this week said the data add to the field’s understanding of PIK3CA-mutated cancers and demonstrate that the PI3 kinase pathway is druggable in solid tumors.